- Heat-triggered release mechanism unequivocally confirmed

- Favorable safety profile with good tolerability

- Signs of encouraging clinical activity in heavily pre-treated patients including meaningful progression-free survival (PFS)

- One participant with previously unresectable disease in DL2 underwent surgery, indicating no vital tumor cells in the target lesion

Munich, Germany – June 24, 2025 – Thermosome GmbH, a clinical-stage drug development company focused on targeted tumor therapies, today announced new, encouraging data from its ongoing Phase 1 clinical trial evaluating its lead compound THE001 (DPPG2-TSL-DOX) in combination with regional hyperthermia (RHT) for the treatment of soft tissue sarcomas (STS). The Phase 1 study is assessing the safety, pharmacokinetics (PK), and preliminary efficacy of THE001 + RHT in participants with locally advanced unresectable or metastatic STS, who have exhausted all prior treatment options, including standard doxorubicin (DOX).